Apnimed, a clinical-stage pharmaceutical company focused on developing oral medicines to treat Obstructive Sleep Apnea (OSA) and related disorders, today announced that the Company’s management team will participate in the Jefferies Virtual Healthcare Conference, held...
– AD128 is a drug combination under development by Apnimed for the treatment of Obstructive Sleep Apnea – – Phase 2 data from Apnimed’s most advanced drug candidate for Obstructive Sleep Apnea, AD109, anticipated in 2ndquarter of this year – CAMBRIDGE, Mass. May 17,...
– Morningside Ventures Joined by Seligman Investments and Tao Capital Partners – – Company expects to report topline data in Q2 2021 from two Phase 2 trials for AD109 for the treatment of OSA – – Financing will support Initiation of Phase 3 program – CAMBRIDGE, Mass....
